Search Result

Isoforms Recommended:	Adenosine A_2A receptor (A_2AR)

Results for "

A2AR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (23) CD20 (1) Dopamine Receptor (1) Endogenous Metabolite (4) HDAC (1) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (15) Inflammation/Immunology (10) Neurological Disease (13)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18776

A2AR-agonist-1 1 Publications Verification	Adenosine Receptor	Neurological Disease
A2AR-agonist-1 is a potent A2AR and ENT1 agonist with Ki of 4.39 and 3.47 for A2AR and ENT1.

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma ^[2] .

HY-101980

Imaradenant 3 Publications Verification HTL1071; AZD4635	Adenosine Receptor	Cancer
AZD4635 (HTL1071) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a K_i of 1.7 nM and shows >30-fold selectivity over other adenosine receptors .

HY-19532

ZM241385 5+ Cited Publications	Adenosine Receptor	Neurological Disease Cancer
ZM241385 is a potent, high affinity and selective adenosine **A_2a receptor (A_2AR) antagonist with a K_i** value of 1.4 nM ^[2] .

HY-101978

Ciforadenant 5 Publications Verification CPI-444; V81444	Adenosine Receptor	Cancer
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .

HY-149916

A2AR-antagonist-1	Adenosine Receptor	Cancer
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC₅₀=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t_1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .

HY-158057

A2AR/A2BR antagonist 1	Adenosine Receptor	Cancer
A_2AR/A_2BR antagonist 1 (compound 7ai) has a dual antagonistic effect on *A_2AR/A_2BR, with the IC₅₀* values of 11.2 nM and 6.4 nM for *A_2AR* and *A_2BR, respectively. A_2AR/A_2BR* antagonist 1 promotes T cell-mediated cancer cell death .

HY-144672

A2A receptor antagonist 2	Adenosine Receptor	Inflammation/Immunology Cancer
A2A receptor antagonist 2 (Compound 57) is a potent, highly selective *adenosine A_2A* receptor** (A_2AR) antagonist with an IC₅₀ of 8.3 nM .

HY-125602

MNI-444	Adenosine Receptor	Neurological Disease
MNI-444 is a BBB-penetrable ligand of adenosine 2A receptor (A2AR). A2AR is a potential non-dopaminergic target for the research of Parkinson’s disease .

HY-141865

Adenosine receptor antagonist 1	Adenosine Receptor	Cancer
Adenosine receptor antagonist 1 is a *A2aR*-selective antagonist with an IC₅₀ of 0.29 nM and displays 14-fold more selective for *A2aR* than *A2bR*.

HY-103169

SCH442416 2 Publications Verification	Adenosine Receptor	Neurological Disease
SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A_2A receptor (A_2AR), with K_is of 0.048 and 0.5 nM for human and rat A_2AR respectively. SCH442416 displays more than 23000-fold selectivity over A₁R, A_2BR, and A₃R (K_i=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A_2A receptors in rat and primate brain ^[2].

HY-109139A

Taminadenant mesylate NIR178 mesylate; PBF509 mesylate	Adenosine Receptor Others	Cancer
Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA .

HY-109139

Taminadenant 1 Publications Verification NIR178; PBF509	Adenosine Receptor	Neurological Disease Cancer
Taminadenant (NIR178; PBF509) is a highly potent and orally active *adenosine A_2A* receptor** (A_2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with K_B values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response ^[2].

HY-N0092

Inosine Maximum Cited Publications 7 Publications Verification	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] .

HY-129393

Etrumadenant 5+ Cited Publications AB928	Adenosine Receptor	Inflammation/Immunology Cancer
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor *(A2aR/A2bR)* antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities ^[2].

HY-19532S

ZM241385-d7	Isotope-Labeled Compounds Adenosine Receptor	Neurological Disease Cancer
ZM241385-d7 is a deuterated form of ZM241385 (HY-19532). ZM241385 is a potent, high affinity and selective adenosine **A_2a receptor (A_2AR) antagonist with a K_i** value of 1.4 nM ^[2] .

HY-N0092S4

Inosine-13C3	Isotope-Labeled Compounds	Others
Inosine-13C3 is a ¹³C-labeled Inosine that can be used in pharmacokinetic studies of Inosine. Inosine is an agonist of adenosine receptors A₁R and *A_2AR* with anti-inflammatory immunomodulatory, antinociceptive and neuroprotective effects .

HY-145308

Heterobivalent ligand-1	Adenosine Receptor Dopamine Receptor	Neurological Disease
Heterobivalent ligand-1 (compound 26) is a heterobivalent ligand for the Adenosine A 2A-dopamine D 2 receptor heteromer (K_DB1 A_2AR=2.1 nM, K_DB1 D₂R= 0.13 nM) .

HY-N0092R

Inosine (Standard)	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] . In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A_2AR ^[2]. Inosine dose-dependently induces hA_2AR-mediated ERK1/2 phosphorylation ^[2]. Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes . In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice ^[2].

HY-N0092S

Inosine-2,8-d2	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine-2,8-d₂ is the deuterium labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors[1][2][3].

HY-163978

YGZ-331	Adenosine Receptor	Neurological Disease
YGZ-331 is a sedative with a calming effect. YGZ-331 is a derivative of the adenosine nucleoside NGBA, which can increase GABA levels. YGZ-331 exerts a sedative-hypnotic effect by activating A1R and *A2aR, and inhibiting CaMKII* phosphorylation (pCaMKII) levels. YGZ-331 can reduce the spontaneous motor activity of mice .

HY-145406

IHCH-3064	Adenosine Receptor HDAC	Inflammation/Immunology Cancer
IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.

HY-N0092S3

Inosine-13C10,15N4	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine-13C10,15N4 is ¹³C and ¹⁵N labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] .

HY-107018

AR-A 2 AR-A 000002	5-HT Receptor	Neurological Disease
AR-A 2 is a selective 5-HT_1B receptor antagonist, with high affinity to guinea pig cortex 5HT_1B/1D and recombinant guinea pig 5-HT_1B receptors (K_i=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig 5-HT_1D receptor (K_i, 5 nM), and shows an EC₅₀ of 4.5 nM for the guinea pig 5-HT_1B receptor; AR-A 2 can be used in the research of depression and anxiety.

HY-101854

N6-(2-Phenylethyl)adenosine N6-Phenethyladenosine; N6-Phenylethyladenosine	Adenosine Receptor	Inflammation/Immunology Cancer
N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine), an adenosine derivative, is a potent adenosine receptors (AR) agonist with K_i values of 11.8 nM, 30.1 nM, 0.63 nM for rat A₁AR, human A₁AR and hA₃AR, respectively .

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma ^[2] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0092

Inosine 5+ Cited Publications	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Adenosine Receptor Endogenous Metabolite
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] .

HY-N0092R

Inosine (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Adenosine Receptor Endogenous Metabolite
Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] . In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A_2AR ^[2]. Inosine dose-dependently induces hA_2AR-mediated ERK1/2 phosphorylation ^[2]. Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes . In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice ^[2].

Cat. No.	Product Name	Chemical Structure

HY-N0092S

Inosine-2,8-d2
Inosine-2,8-d₂ is the deuterium labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors[1][2][3].

HY-19532S

ZM241385-d7
ZM241385-d7 is a deuterated form of ZM241385 (HY-19532). ZM241385 is a potent, high affinity and selective adenosine **A_2a receptor (A_2AR) antagonist with a K_i** value of 1.4 nM ^[2] .

HY-N0092S4

Inosine-13C3
Inosine-13C3 is a ¹³C-labeled Inosine that can be used in pharmacokinetic studies of Inosine. Inosine is an agonist of adenosine receptors A₁R and *A_2AR* with anti-inflammatory immunomodulatory, antinociceptive and neuroprotective effects .

HY-N0092S3

Inosine-13C10,15N4
Inosine-13C10,15N4 is ¹³C and ¹⁵N labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

A2AR

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products